Research and Clinical Trials

Brief Description  
Neuroscience and Spine Institute (NSSI) and Carolinas HealthCare System (CHS) is participating in a research study to investigate CK-2017357 as a potential new therapy for improvement of muscle weakness and muscle fatigue in Amyotrophic Lateral Sclerosis (ALS) patients. The study is sponsored by Cytokinetics, Inc. The purpose of this study is to evaluate the safety of CK-2017357 and how well it is tolerated in patients with ALS, also known as Lou Gehrig’s disease. This research study will
Who may be Eligible  
Male and females over the age of 18 with a diagnosis of ALS.
ALS - Amyotrophic Lateral Sclerosis
IRB Number  
Principal Investigator  
Brooks, Benjamin

For More Information, Contact  Rachel  M, Skains
Phone:  (704) 442-6253  Fax:  (704) 446-1910  
Address:1010 Edgehill Road North Charlotte, NC 28207